System1 Sees Q2 Revenue $146M-$149M Vs $214.5M Est.

Second Quarter 2023 Guidance The Company expects for the second quarter of 2023: Revenue between $146 million and $149 million. Gross Profit between $41.5 million and $43.5 million Adjusted Gross Profit between $53 million and $55 million. Adjusted EBITDA between $17 million and $19 million.

Second Quarter 2023 Guidance

The Company expects for the second quarter of 2023:

Revenue between $146 million and $149 million.
Gross Profit between $41.5 million and $43.5 million
Adjusted Gross Profit between $53 million and $55 million.
Adjusted EBITDA between $17 million and $19 million.
In reliance on the unreasonable efforts exception for forward-looking information provided under Regulation S-K, the Company is not reasonably able to provide a quantitative reconciliation of Adjusted Gross Profit and Adjusted EBITDA to the most directly comparable GAAP financial measures without unreasonable effort due to uncertainties regarding purchase accounting, stock-based compensation, taxes and other potential adjustments. The variability of these items could have an unpredictable, and potentially significant, impact on the Company’s future GAAP financial results. For the second quarter of 2023, the Company expects interest expense in the range of $12 million to $13 million, depreciation and amortization expense in the range of $27 million to $29 million, and select non-recurring items including Protected.net acquisition bonus accrual expense in the range of $13 million to $14 million, and acquisition and restructuring costs to be in the range of $2.5 million to $4.5 million.

The Company’s achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.S. Securities and Exchange Commission. The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of the Company’s acquisitions, dispositions or financings during 2023.

Total
0
Shares
Related Posts
Read More

Infinity Pharmaceuticals Provides Additional Information On MARIO-8 Study Evaluating Eganelisib In Combination With The PD-1 Targeted Checkpoint Inhibitor Pembrolizumab In Patients With Squamous Cell Cancer Of The Head And Neck

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate,

INFI